Download
1 / 3
30 likes | 45 Vues
Prostate cancer is caused by the uncontrolled growth of the cells in the prostate gland. Prostate cancer is the most common cancer in men in the U.S., after skin cancer.
E N D
Prostate Cancer Therapeutics Market Set to Gain Traction over the Forecast Period 2018-2026 Prostate Cancer Therapeutics Market, by Drug Type (Hormonal Therapy, Anti-androgens, Immunotherapy, Targeted Therapy, and Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Geography - Global Trends, and Forecast to 2025 Prostate Cancer Therapeutics Market Insights Prostate cancer is caused by the uncontrolled growth of the cells in the prostate gland. Prostate cancer is the most common cancer in men in the U.S., after skin cancer. According to the American Community Survey, 2016, in U.S. prostate cancer is the second leading cause of death among the cancer deaths in men. Almost all prostate cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fuids). Other types of prostate cancer are rare; these include: Sarcomas, small cell carcinomas, neuroendocrine tumors and transitional cell carcinomas. Advanced stage of prostate cancer can cause men to urinate more often or have a weaker fow of urine, but these symptoms can also be caused by benign prostate conditions. In 2017, the American Cancer Society estimated around 161,360 new diagnoses of prostate cancer in the U.S., leading to around 26,730 fatalities. As the cause of the cancer is not known, there is no defnite way to prevent prostate cancer. The American Cancer Society (ACS) and the National Comprehensive Cancer Network (NCCN) recommends that all men over age 40 should have an annual rectal examination and that men have an annual prostate-specifc antigen (PSA) test beginning at age of 50 years.
Download PDF Brochure of Market Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1257 Endeavor to introduce highly efective therapies for prostate cancer would support the market growth Many research organizations and universities are investing in research for the development of therapeutic products for the treatment of such tumors. For instance, some pipeline products which are in phase 2 studies, such as Avelumab (Duke University Medical Center), Metformin (Mansoura University), LY2452473 (Dana-Farber Cancer Institute) are expected to arrive in the market in the near future. Furthermore, many products that are about to face patent expiry during the forecast period will also contribute in the growth of the generic prostate cancer therapeutics market. Many pharmaceutical companies are also focusing on introducing their respective drugs in diferent countries to boost the sales of their products. For instance, in December, 2016, Sanofis prostate cancer drug name Jevtana (cabazitaxel) for the treatment of metastatic hormone-refractory prostate cancer (mHRPC) was approved by Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland, due to which Scotland has now collaborated with health authorities in Northern Ireland, England and Wales. Thereby, reducing potential disparities in care across the UK for this vulnerable group of patients. Browse more about the Deep Brain Stimulation Devices Market Study: https://www.coherentmarketinsights.com/insight/request-customization/24 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting frm ofering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com
